A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NCT00001123 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

130

Enrollment

NIH

Sponsor class

Conditions

Hantavirus Pulmonary Syndrome

Interventions

DRUG: Ribavirin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)